尼莫地平治疗脑卒中后认知功能障碍的疗效观察

目的探讨尼莫地平对脑卒中后认知功能障碍的改善作用。方法将145例卒中后认知功能障碍患者随机分为两组,对照组常规治疗原发病、康复训练及心理支持;治疗组在此基础上同时合并使用尼莫地平片30 mg,3次/d,各组患者观察治疗至4周末。在治疗前及治疗后4周进行蒙特利尔认知评估量表(Montreal Cognitive Assessment,MoCA)评分。结果两组患者治疗前采用MoCA评分,差异无统计学意义(P>0.05);对照组治疗4周后MoCA评分有所改善,但与治疗前对比差异无统计学意义(P>0.05),治疗组治疗4周后MoCA评分明显改善,表现在记忆力、视空间与执行功能及总分方面差异有统计学意义(P<0.05)。结论尼莫地平治疗脑卒中后认知功能障碍的疗效确切。

The Efficacy Observation of Nimodipine on Cognitive Dysfunction in Patients with Post-Stroke

Objective To observe Nimodipine in patients of post-stroke on cognitive function improvement.Methods 145 cases of post-stroke patients with Cognitive dysfunction were randomly divided into two groups,the control group with conventional treatment of the primary disease,rehabilitation training and psychological support;the treatment group at the same time on the basis of a combination of Nimodipine tablets with 30mg,3 times one day,each group of patients with treatment and follow-up to the end of the 4th week.The Montreal Cognitive Assessment Scale(Montreal Cognitive Assessment,MoCA) were used at Pre-treatment and treatment at the end of 4 weeks.Results MoCA Scale score showed no statistical difference between two groups of patients before treatment(P>0.05);4 weeks after treatment,MoCA Scale score of the control group showed improvement,but no statistical difference was observed when compared with Pre-treatment(P>0.05),and MoCA Scale score of the treatment group show significantly improvement,with statistical difference on the faculty of memory and visuopatial/executive(P<0.05).Conclusion The efficacy of Nimodipine on cognitive function improvement in patients of post-stroke was confirmed.